Crit Care Med:脓毒症和感染性休克对癌症患者的影响

2020-04-25 MedSci原创 MedSci原创

随着时间的推移,患脓毒症的危重肿瘤和血液系统肿瘤患者的生存率显著提高。随着结局的改善,临床医生应考虑更新此类人群的入院政策和治疗目标。

癌症影响多达20%的重症患者,脓毒症是在这类患者入住ICU的主要原因之一。早期预警表明可能会提高该人群的存活率,但是缺乏明确的研究。近日,危重病医学领域权威杂志Critical Care Medicine上发表了一篇研究文章,这项研究旨在评估过去20年中因脓毒症或感染性休克而入住ICU的癌症患者随时间推移的存活率趋势情况。

该研究的数据来源于七个欧洲ICU,将入院年份和数据集来源作为随机变量的层次模型用于确定30天死亡率的危险因素。研究人员提取了因脓毒症或感染性休克入住ICU的癌症患者数据。

总体而言,该研究纳入了2062名患者(62%的男性,中位[四分位间距]年龄为59岁[48-67岁])。潜在的恶性肿瘤为实体瘤(n=362; 17.6%)或血液系统恶性肿瘤(n=1700; 82.4%),包括急性白血病(n=591; 28.7%)、非霍奇金淋巴瘤(n=461; 22.3%)和骨髓瘤(n=244;11.8%)。在入住ICU时,有250名患者(12%)接受了异基因造血干细胞移植,而640名患者(31.0%)为中性粒细胞减少症患者。第30天的死亡率为39.9%(823例死亡)。入住ICU的年份与第30天的死亡率随时间显著降低有关(比值比为0.96;95%CI为0.93-0.98; p=0.001)。机械通气(比值比为3.25;95%CI为2.52-4.19;p<0.01)和使用升压药(比值比为1.42;95%CI为1.10-1.83;p<0.01)与第30天的死亡率独立相关,而潜在的恶性肿瘤、同种异体造血干细胞移植和中性粒细胞减少则与之无关。

由此可见光,随着时间的推移,患脓毒症的危重肿瘤和血液系统肿瘤患者的生存率显著提高。随着结局的改善,临床医生应考虑更新此类人群的入院政策和治疗目标。

原始出处:

Lemiale, Virginie.et al.Sepsis and Septic Shock in Patients With Malignancies.critical care medicine.2020.https://journals.lww.com/ccmjournal/Abstract/9000/Sepsis_and_Septic_Shock_in_Patients_With.95680.aspx

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1004073, encodeId=fbef10040e3ba, content=<a href='/topic/show?id=2a575331391' target=_blank style='color:#2F92EE;'>#感染性休克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53313, encryptionId=2a575331391, topicName=感染性休克)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=小小医者, createdTime=Fri Jul 30 22:14:24 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655488, encodeId=203216554882d, content=<a href='/topic/show?id=7c2853311ac' target=_blank style='color:#2F92EE;'>#感染性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53311, encryptionId=7c2853311ac, topicName=感染性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=583d24724321, createdName=charl1234575, createdTime=Tue Sep 01 01:20:39 CST 2020, time=2020-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289673, encodeId=b08112896e322, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Mon Apr 27 09:20:39 CST 2020, time=2020-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610456, encodeId=f3ad16104562b, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Mon Apr 27 09:20:39 CST 2020, time=2020-04-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1004073, encodeId=fbef10040e3ba, content=<a href='/topic/show?id=2a575331391' target=_blank style='color:#2F92EE;'>#感染性休克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53313, encryptionId=2a575331391, topicName=感染性休克)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=小小医者, createdTime=Fri Jul 30 22:14:24 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655488, encodeId=203216554882d, content=<a href='/topic/show?id=7c2853311ac' target=_blank style='color:#2F92EE;'>#感染性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53311, encryptionId=7c2853311ac, topicName=感染性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=583d24724321, createdName=charl1234575, createdTime=Tue Sep 01 01:20:39 CST 2020, time=2020-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289673, encodeId=b08112896e322, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Mon Apr 27 09:20:39 CST 2020, time=2020-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610456, encodeId=f3ad16104562b, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Mon Apr 27 09:20:39 CST 2020, time=2020-04-27, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1004073, encodeId=fbef10040e3ba, content=<a href='/topic/show?id=2a575331391' target=_blank style='color:#2F92EE;'>#感染性休克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53313, encryptionId=2a575331391, topicName=感染性休克)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=小小医者, createdTime=Fri Jul 30 22:14:24 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655488, encodeId=203216554882d, content=<a href='/topic/show?id=7c2853311ac' target=_blank style='color:#2F92EE;'>#感染性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53311, encryptionId=7c2853311ac, topicName=感染性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=583d24724321, createdName=charl1234575, createdTime=Tue Sep 01 01:20:39 CST 2020, time=2020-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289673, encodeId=b08112896e322, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Mon Apr 27 09:20:39 CST 2020, time=2020-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610456, encodeId=f3ad16104562b, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Mon Apr 27 09:20:39 CST 2020, time=2020-04-27, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1004073, encodeId=fbef10040e3ba, content=<a href='/topic/show?id=2a575331391' target=_blank style='color:#2F92EE;'>#感染性休克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53313, encryptionId=2a575331391, topicName=感染性休克)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=小小医者, createdTime=Fri Jul 30 22:14:24 CST 2021, time=2021-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655488, encodeId=203216554882d, content=<a href='/topic/show?id=7c2853311ac' target=_blank style='color:#2F92EE;'>#感染性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53311, encryptionId=7c2853311ac, topicName=感染性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=583d24724321, createdName=charl1234575, createdTime=Tue Sep 01 01:20:39 CST 2020, time=2020-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289673, encodeId=b08112896e322, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Mon Apr 27 09:20:39 CST 2020, time=2020-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610456, encodeId=f3ad16104562b, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Mon Apr 27 09:20:39 CST 2020, time=2020-04-27, status=1, ipAttribution=)]
    2020-04-27 智慧医人

相关资讯

免疫激活剂7HP349的研究性新药申请,获得FDA的批准

整联蛋白细胞粘附分子(例如α4β1和αLβ2)对于抗原呈递和免疫激活至关重要。

上海发布全新数据:癌症患病率3% 5年生存率年均增长1%

上海4月15日电 (记者 陈静)肿瘤是影响上海民众健康的主要慢性疾病之一 。上海市卫健委15日披露的最新数据显示,上海目前有癌症现患病人45万,患病率达到3%。癌症是此间民众第二位死因。

Nature:胆汁酸代谢物化身“抗癌战士”,大大阻断癌症高危因素产生!

癌症可谓是肠道微生物诸多相关研究中最浓墨重彩的一笔。大量研究表明,一些肠道微生物可以促进癌症的发生、帮助癌细胞转移、导致化疗耐药和影响免疫治疗的效果,可以说是全方位,多角度。近日,路德维希癌症在这一领

OPEN BIO:癌症进化研究或可催生抗癌新疗法

以改变癌细胞进化的微环境为基础研发抗癌新疗法,极有可能兼具可行性与有效性。

AP&T:老年炎症性肠病患者感染或癌症风险更高

对于老年炎症性肠病(IBD)患者,与生物疗法相关的感染和癌症风险存在不确定性。本项研究旨在探究老年炎症性肠病患者感染或癌症风险。

Science:单个细胞分裂错误可能触发一系列具癌症特征的突变

导言:癌症基因组可以包含数百个染色体重排。传统观点认为,它们在许多代中都会发生小规模的变化,但是许多癌症中的大量重排表明,这些基因组实际上可能会通过产生基因组突变的不连续片段而快速进化。